Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2025-11.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96 Cyclooxygenase and Prostaglandin in Cancer
Skip Navigation
Skip to contents

Ann Coloproctol : Annals of Coloproctology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > J Korean Soc Coloproctol > Volume 28(5); 2012 > Article
Editorial
 Cyclooxygenase and Prostaglandin in Cancer
Jong-Woo Kim
Journal of the Korean Society of Coloproctology 2012;28(5):226-227.
DOI: https://doi.org/10.3393/jksc.2012.28.5.226
Published online: October 31, 2012

Department of Surgery, Bundang CHA Hospital, CHA University College of Medicine, Seongnam, Korea.

Correspondence to: Jong-Woo Kim, M.D. Department of Surgery, Bundang CHA Hospital, CHA University College of Medicine, 59 Yatap-ro, Bundang-gu, Seongnam 463-712, Korea. Tel: +82-31-780-5250, Fax: +82-31-780-5259, kjw@cha.ac.kr

© 2012 The Korean Society of Coloproctology

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next
  • 2,985 Views
  • 37 Download
Full Article

Download PDF Download PDF

See Article on Page [Related article:] 253-258
Inflammation, especially longstanding abnormal inflammation, seems to contribute to neoplastic transformation to some extent. We cannot help thinking of cyclooxygenase (Cox) and prostaglandin (PG) whenever we mention it. Three isoenzymes of Cox have been identified so far: Cox-1, Cox-2, and Cox-3, but Cox-3, recently identified, is a variant of Cox-1 and is also called Cox-1v. It is formed from a frame shift of the original Cox-1 gene, but it seems not to play usual Cox physiologic roles as in inflammation and fever, and it is still being studied [1, 2]. Although Cox-1 and Cox-2 enzymes basically work in the same way, they are expressed in different ways and at different levels in various organs and tissues. That is the reason side effects are different from selective inhibition against each enzyme. Cox-1, as a constitutional enzyme, is expressed from most cells in homeostatic processes and is inhibited in feedback. On the other hand, Cox-2 is mostly an enzyme that is induced under certain conditions such as inflammation or neoplastic process, but is rarely inhibited. Therefore, Cox-2 selective inhibitors effectively play their roles, especially at inflammatory sites, and do not damage the mucosa protection of gastric tissue without prohibiting the secretion of Cox-1, which is easily blocked by nonsteroidal antiinflammatory drugs (NSAIDs) in general. However, the selectivity of Cox-2 inhibitors does not seem to relieve other side effects of NSAIDs. Recently, increased risks of heart attack, cerebral stroke and renal failure have been reported with Cox-2 selective inhibitors, which seems to result from the reduced level of prostacyclin caused by Cox-2 inhibition. Prostacyclin has an important role in preventing platelets aggregation and blood clotting [3, 4].
As we know, Cox converts arachidonic acid in the cell membrane to prostaglandin H2, the precursor of the final series-2 prostanoids such as PGE2, PGD2, PGF2, PGI2, and thromboxane A2. PGE2, one of the final products, is well known for its activities, such as softening the cervix, uterine contraction, inducing abortion, etc., in obstetric field [5]. However, the important thing is that PGE2 has recently been shown to have a strong relation with tumorigenesis in that it increases cell proliferation, angiogenesis and metastatic potential, and inhibits apoptosis and cellular immunity, which seem to be due to the increased expression of PGE2 by Cox-2 because excessive levels of PGE2 and Cox-2 are implicated in mediating several kinds of malignancies. However, we must also consider the Cox-2 activity in tumor tissue on its own without mediating prostaglandins. It can behave directly for tumorigenesis with activities similar to those mentioned above. For example, Cox-2 directly increases the intranuclear nuclear factor-κB, which is the main stimulus for gene activation and replication, and forms endogenous mutagen, malondialdehyde, from arachidonic acid, which can cause a mutation of p53, and stimulates vascular endothelial growth factor for angiogenesis [6, 7].
15-hydroxyprostaglandin dehydrogenase (15-PGDH) is supposed to degrade PGE2 selectively, and decreased expression of 15-PGDH might also be related with cancer as previously reported [8, 9]. As the author has mentioned, selective PGE2 inhibitors would work for the prevention or treatment of cancer if it developed. However, considering the direct effects of Cox-2 on carcinogenesis, cancer is unfortunately not that simple to get over. Therefore, selective PGE2 inhibitors will continue to be just one of many ordinary agents, but one that has a slight benefit in treating cancer. However numerous, these sorts of studies should form a basis for the future conquest of cancer.
  • 1. Kis B, Snipes JA, Gaspar T, Lenzser G, Tulbert CD, Busija DW. Cloning of cyclooxygenase-1b (putative COX-3) in mouse. Inflamm Res 2006;55:274–278. ArticlePubMed
  • 2. Schneider C, Boeglin WE, Brash AR. Human cyclo-oxygenase-1 and an alternative splice variant: contrasts in expression of mRNA, protein and catalytic activities. Biochem J 2005;385(Pt 1): 57–64. ArticlePubMed
  • 3. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009;17:55–67. ArticlePubMed
  • 4. Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, et al. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010;209:155–162. ArticlePubMed
  • 5. Maybin JA, Hirani N, Jabbour HN, Critchley HO. Novel roles for hypoxia and prostaglandin E2 in the regulation of IL-8 during endometrial repair. Am J Pathol 2011;178:1245–1256. ArticlePubMedPMC
  • 6. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett 2010;295:7–16. ArticlePubMed
  • 7. Sharma RA, Gescher A, Plastaras JP, Leuratti C, Singh R, Gallacher-Horley B, et al. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 2001;22:1557–1560. ArticlePubMedPDF
  • 8. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217–3223. ArticlePubMed
  • 9. Lou LH, Jing DD, Lai YX, Lu YY, Li JK, Wu K. 15-PGDH is reduced and induces apoptosis and cell cycle arrest in gastric carcinoma. World J Gastroenterol 2012;18:1028–1037. ArticlePubMedPMC

Figure & Data

References

    Citations

    Citations to this article as recorded by  

      • Cite this Article
        Cite this Article
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Cyclooxygenase and Prostaglandin in Cancer
        J Korean Soc Coloproctol. 2012;28(5):226-227.   Published online October 31, 2012
        DOI: https://doi.org/10.3393/jksc.2012.28.5.226
        Close
      • XML DownloadXML Download
      Cyclooxygenase and Prostaglandin in Cancer
      Cyclooxygenase and Prostaglandin in Cancer
      Ann Coloproctol : Annals of Coloproctology Twitter Facebook
      © Korean Society of Coloproctology.
      TOP